A Rational Approach to the Management of Chronic Migraine

@article{Evans2013ARA,
  title={A Rational Approach to the Management of Chronic Migraine},
  author={Randolph W. Evans},
  journal={Headache: The Journal of Head and Face Pain},
  year={2013},
  volume={53}
}
  • R. Evans
  • Published 1 January 2013
  • Medicine
  • Headache: The Journal of Head and Face Pain
About 2% of the adult population has chronic migraine with only 20% diagnosed with this disorder. Those with medication overuse may improve with withdrawal of overuse medications. The intravenous dihydroergotamine regimen usually produces short‐term benefit for those with medically refractory chronic migraine. OnabotulinumtoxinA and topiramate have shown efficacy in large placebo‐controlled randomized trials. Sodium valproate, gabapentin, tizanidine, amitriptyline, fluoxetine, zonisamide, and… Expand
Pharmacologic Approaches to CDH: Evidence and Outcomes
TLDR
Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of chronic migraine (CM), and there are other neuromodulators, beta-blockers, calcium channel blockers, or antidepressants useful in the management of this population of patients. Expand
Drug Treatment for Chronic Migraine
TLDR
The primary goals of preventive therapy in subjects with chronic migraine are to reduce the frequency and severity of attacks, to reduce reliance on acute medications, and to improve quality of life. Expand
Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society
TLDR
A pathogenetic model for CM is provided, integrating the latest findings from neurophysiological and neuroimaging studies, and an integrated multimodal treatment programme may be beneficial to refractory patients. Expand
Medication overuse and chronic migraine: a critical review according to clinical pharmacology
TLDR
This narrative review describes how to try to prevent the development of MOH and how to manage it once it has appeared, and detects disease biomarkers and predictive factors for drug response that allow for personalized treatment when migraine is still episodic and make analgesic overuse pointless. Expand
Refractory migraine: the role of the physician in assessment and treatment of a problematic disease
TLDR
An escalating approach is suggested to test different kinds of therapies to improve headache-related quality of life, and more invasive modalities or promising approaches such as repetitive transcranial magnetic stimulation could be a future major step as third line therapies. Expand
Chronic Daily Headache: Mechanisms and Principles of Management
Primary headache is a common malady that is often under-recognized and frequently inadequately managed in spite of the fact that it affects up to 95 % of the population in a lifetime. Many forms ofExpand
The Pharmacological Treatment of Migraine in Brazil
TLDR
The aim of this review is to perform a general description of the pharmacological treatments of migraine in tertiary headache centers of Brazil. Expand
[Diagnosis of refractory forms of chronic primary headache].
TLDR
Diagnostic criteria for the most important forms such as refractory chronic migraine or refractor chronic cluster headache presented by experts of the European Headache Federation in two separate Consensus are discussed. Expand
Tackling chronic migraine: current perspectives
TLDR
Management includes identification and control of comorbidities and risk factors that predispose to CM; treatment and prevention for medication overuse; early treatment for migraine attacks; and an adequate preventive therapy for CM. Expand
Comparison between Intravenous Sodium Valproate and Subcutaneous Sumatriptan for Treatment of Acute Migraine Attacks; Double-Blind Randomized Clinical Trial
TLDR
Intravenous SV (400 mg) was as effective as subcutaneous Sumatriptan in the treatment of acute migraine attacks, but with more improvement in associated symptoms and with fewer side effects. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 87 REFERENCES
Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse
TLDR
Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present. Expand
Detoxification for medication overuse headache is not necessary
  • H. Diener
  • Medicine
  • Cephalalgia : an international journal of headache
  • 2012
TLDR
It is proposed to educate patients on the mechanisms of medication overuse and motivate them to reduce intake frequency and patients who fail should be offered either topiramate or onabotulinum toxin A in combination with behavioural therapy and regular exercise. Expand
[Zonisamide in the preventive treatment of refractory migraine].
TLDR
The results, obtained in a big sample of patients refractory or intolerant to topiramate and other preventatives, indicate that, at least in conditions of daily clinical practice, zonisamide, at relatively low dosages, is an option to be considered for the preventive treatment of patients with frequent migraine. Expand
Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial
TLDR
This is the first randomized controlled trial demonstrating the benefits of nabilone on headache, analgesic consumption and the quality of life in patients with intractable MOH and this drug appears to be safe and well-tolerated. Expand
Pregabalin in the Treatment of Chronic Migraine: An Open-Label Study
TLDR
The data suggest that pregabalin may be a useful alternative prophylaxis for chronic migraine, and promising results should be confirmed in randomized clinical trials. Expand
Occipital nerve stimulation for chronic migraine: a randomized trial.
TLDR
OnS appears to be a safe and effective treatment for carefully selected CM and MOH patients and to evaluate changes in disability, quality of life, and drug intake in implanted patients. Expand
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
TLDR
The International Headache Classification Committee has worked out the more inclusive criteria for CM and MOH and it is now recommended that the MOH diagnosis should no longer request improvement after discontinuation of medication overuse but should be given to patients if they have a primary headache plus ongoing medication over use. Expand
Discontinuation of Medication Overuse in Headache Patients: Recovery of Therapeutic Responsiveness
TLDR
It is found that after 1 year, those who had stopped their overuse had a reduction in the number of headache days of the order of 73.7%, vs. just 17.2% in those who continued to overuse. Expand
Topiramate Reduces Headache Days in Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study
TLDR
This randomized, double-blind, placebo-controlled trial demonstrates that topiramate is effective and reasonably well tolerated when used for the preventive treatment of chronic migraine, even in the presence of medication overuse. Expand
Intravenous dihydroergotamine for inpatient management of refractory primary headaches
TLDR
The data suggest that IV dihydroergotamine given over 5 days produces improvement in headache and disability in patients with migraine more than shorter courses, and longer treatments produce a better outcome. Expand
...
1
2
3
4
5
...